Exelixis
EXEL
#1602
Rank
NZ$17.63 B
Marketcap
$63.02
Share price
-3.32%
Change (1 day)
60.00%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.47

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.50. In 2022 the company made an earnings per share (EPS) of $1.01 a decrease over its 2021 EPS that were of $1.32.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.47-53.88%
2022$1.01-22.97%
2021$1.32100%
2020$0.66-65.09%
2019$1.88-53.91%
2018$4.09333.96%
2017$0.94-260.61%
2016-$0.59-58.75%
2015-$1.42-42.45%
2014-$2.475.3%
2013-$2.3543.48%
2012-$1.64-264.29%
2011$1.00-165.88%
2010-$1.51-32.54%
2009-$2.24-17.65%
2008-$2.7275.86%
2007-$1.55-25.64%
2006-$2.088.33%
2005-$1.92-42.86%
2004-$3.3630.34%
2003-$2.58-5.23%
2002-$2.72-0.65%
2001-$2.74-51.88%
2000-$5.69

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$6.22 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.65 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$3.24 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.06 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$25.15 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$25.03 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.31 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$17.77-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.49-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA